{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000007","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.144695+00:00","generated_at":"2026-06-07T02:47:40.161743+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Boston Scientific to acquire Axonics for $71.00 per share in cash","bullets":["Each Axonics share will be converted into $71.00 in cash, without interest.","Termination fee of $75M payable by Axonics for superior proposal; $140M payable by Boston Scientific if antitrust fails after Axonics stockholder approval.","Transaction subject to Axonics stockholder approval, HSR waiting period, and other regulatory consents.","Axonics board unanimously recommends adoption of the merger agreement.","Customary no-shop clause with fiduciary out allows Axonics to consider superior proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000007","json":"https://secwatch.observer/filing/0000885725-24-000007.json","markdown":"https://secwatch.observer/filing/0000885725-24-000007.md","text":"https://secwatch.observer/filing/0000885725-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000007/0000885725-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000007/bsx-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:47:40.161743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18b26e7dec6e76966efea388096277cc51a39169","claim":"BOSTON SCIENTIFIC CORP entered into Agreement and Plan of Merger with Axonics, Inc. valued at Merger consideration of $71.00 per share in cash (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Axonics, Inc., a Delaware corporation (“ Axonics ”), providing for the merger of Merger Sub with and into Axonics (the “ Merger ”), with Axonics surviving the Merger as a wholly owned subsidiary of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000007/0000885725-24-000007-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Axonics, Inc."},{"label":"Value","value":"Merger consideration of $71.00 per share in cash"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}